Healthy Regulatory T (TReg) Cells
Regulatory T (TReg) cells are essential for suppressing immune cells.
They maintain immune tolerance to prevent autoimmune and inflammatory diseases
Dysfunctional Regulatory T (TReg) Cells
Dysregulation of IL-2 receptor signaling is linked to dysfunctional Tregs
Dysfunctional Tregs contribute to autoimmune diseases through:
- Failure to suppress other immune cells
- Loss of self-tolerance
- Lack of proper co-stimulation / downregulation of their suppressive mechanisms
Our SCIENCE Has...
Identified the Core Defect:
We have determined that dysregulated IL-2 receptor (IL-2R) signaling represents a shared functional impairment in Tregs isolated from patients with autoimmune disease
Elucidated IL-2R Regulatory Mechanisms:
We have employed proprietary genomic and proteomic screening platforms to identify key molecular regulators of IL-2R signaling in Tregs
Restored Critical Downstream Pathways:
We have successfully corrected IL-2R signaling dysfunction and re-established pSTAT5 activation, a pathway essential for Treg function and maintenance of immune tolerance
Engineered Targeted Protein Drug Conjugates (PDCs):
We have developed Treg-selective PDCs designed to repair IL-2R signaling defects and restore robust, durable immunoregulatory activity
TRegRx has developed a novel protein-drug conjugate (PDC) platform that repairs defective IL-2 receptor (IL-2R) signaling in Tregs, restoring immune balance without broad immunosuppression.
TRegRx is advancing its Protein Drug Conjugate (PDC) platform toward preclinical IND-enabling studies with the goal of entering first-in-human trials in type 1 diabetes, multiple sclerosis, and systemic lupus erythematosus, followed by additional programs in rheumatoid arthritis, inflammatory bowel disease and severe asthma.
Protein Drug Conjugates (PDCs): Just Like An ADC,
But 100-Fold More Efficient